Paper23782898
The metabolism of primaquine to its active metabolite is dependent on CYP 2D6.
Pybus BS and 13 others. Malar J, 2013. Cited by 146 papers, by iCite.
Cite this record
ConductScience Library. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Papers, record 23782898. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23782898
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antimalarials | Major topic |
| Cytochrome P-450 CYP2D6 | Major topic |
| Primaquine | Major topic |
| Animals | |
| Hydroxylation | |
| Malaria | |
| Male | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Knockout | |
| Plasmodium berghei |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02898779 | Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1 | Results | ClinicalTrials.gov | |
| NCT05071079 | A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes | Background | ClinicalTrials.gov |
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22144436 | Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations. | Am J Trop Med Hyg | 2011 | https://conductscience.org/library/papers/22144436 | PubMed |
| 2 | 11972444 | CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. | Pharmacogenomics | 2002 | https://conductscience.org/library/papers/11972444 | PubMed |
| 3 | 11303037 | Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline. | J Pharmacol Exp Ther | 2001 | https://conductscience.org/library/papers/11303037 | PubMed |
| 4 | 1313024 | Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling. | J Biol Chem | 1992 | https://conductscience.org/library/papers/1313024 | PubMed |
| 5 | 18930565 | Primaquine revisited six decades after its discovery. | Eur J Med Chem | 2009 | https://conductscience.org/library/papers/18930565 | PubMed |
| 6 | 23130957 | Rationale for short course primaquine in Africa to interrupt malaria transmission. | Malar J | 2012 | https://conductscience.org/library/papers/23130957 | PubMed |
| 7 | 14618296 | Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. | Naunyn Schmiedebergs Arch Pharmacol | 2004 | https://conductscience.org/library/papers/14618296 | PubMed |
| 8 | 21171195 | How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments. | Curr Drug Metab | 2010 | https://conductscience.org/library/papers/21171195 | PubMed |
| 9 | 21989258 | Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. | Mol Pharmacol | 2012 | https://conductscience.org/library/papers/21989258 | PubMed |
| 10 | 17075340 | 8-Aminoquinolines: future role as antiprotozoal drugs. | Curr Opin Infect Dis | 2006 | https://conductscience.org/library/papers/17075340 | PubMed |
| 11 | 19616568 | Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. | Toxicol Appl Pharmacol | 2009 | https://conductscience.org/library/papers/19616568 | PubMed |
| 12 | 10445386 | Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine. | Exp Toxicol Pathol | 1999 | https://conductscience.org/library/papers/10445386 | PubMed |
| 13 | 7720510 | Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes. | Drug Metab Dispos | 1995 | https://conductscience.org/library/papers/7720510 | PubMed |
| 14 | 14724225 | Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine. | J Pharmacol Exp Ther | 2004 | https://conductscience.org/library/papers/14724225 | PubMed |
| 15 | 22972117 | Primaquine for reducing Plasmodium falciparum transmission. | Cochrane Database Syst Rev | 2012 | https://conductscience.org/library/papers/22972117 | PubMed |
| 16 | 22662135 | Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance. | PLoS One | 2012 | https://conductscience.org/library/papers/22662135 | PubMed |
| 17 | 12438535 | Primaquine-induced hemolytic anemia: formation of free radicals in rat erythrocytes exposed to 6-methoxy-8-hydroxylaminoquinoline. | J Pharmacol Exp Ther | 2002 | https://conductscience.org/library/papers/12438535 | PubMed |
| 18 | 12235244 | Primaquine-induced hemolytic anemia: effect of 6-methoxy-8-hydroxylaminoquinoline on rat erythrocyte sulfhydryl status, membrane lipids, cytoskeletal proteins, and morphology. | J Pharmacol Exp Ther | 2002 | https://conductscience.org/library/papers/12235244 | PubMed |
| 19 | 22856549 | CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. | Malar J | 2012 | https://conductscience.org/library/papers/22856549 | PubMed |
| 20 | 4060148 | Structure-activity relationships of putative primaquine metabolites causing methemoglobin formation in canine hemolysates. | Toxicol Appl Pharmacol | 1985 | https://conductscience.org/library/papers/4060148 | PubMed |
Cited by114
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 146 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42888416 | CYP3A and CYP2D6 variability in antimalarial pharmacokinetics and pharmacogenetics across populations: a narrative review. | Malar J | 2026 | https://conductscience.org/library/papers/42888416 | PubMed |
| 42531257 | An orally available PfPKG inhibitor blocks Plasmodium's infection of the liver. | PLoS Pathog | 2026 | https://conductscience.org/library/papers/42531257 | PubMed |
| 42439801 | Primaquine-derived 5,6-orthoquinone concentrations in urine associated with CYP2D6 genotype-predicted phenotype and blood methemoglobin levels. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/42439801 | PubMed |
| 42037398 | Differential impact of Tafenoquine and Primaquine on Plasmodium vivax recurrence: the role of CYP2D6 variants. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/42037398 | PubMed |
| 41320957 | Humanization of Drug Metabolism in the Plasmodium berghei Mouse Model for Antimalarial Drug Discovery. | ACS Infect Dis | 2025 | https://conductscience.org/library/papers/41320957 | PubMed |
| 41097408 | Discovery of Primaquine-Indole Carboxamides with Cancer-Cell-Selective Antiproliferative Activity. | Molecules | 2025 | https://conductscience.org/library/papers/41097408 | PubMed |
| 41028863 | Enhancing CYP2D6 genotyping with nanopore sequencing to address allele diversity P. vivax malaria elimination. | Sci Rep | 2025 | https://conductscience.org/library/papers/41028863 | PubMed |
| 40827872 | How CYP2D6 Polymorphism Modulates the Community-Wide Risk of Plasmodium vivax Infection: A Panel Study in Amazonian Brazil. | J Infect Dis | 2025 | https://conductscience.org/library/papers/40827872 | PubMed |
| 40420292 | Natural products as transmission-blocking agents against malaria: a comprehensive review of bioactive compounds and their therapeutic potential. | Malar J | 2025 | https://conductscience.org/library/papers/40420292 | PubMed |
| 40316617 | Impact of CYP2D6, MAOA, and UGT2B7 genetic variants on recurrence of Plasmodium Vivax in the Brazilian Amazon. | Sci Rep | 2025 | https://conductscience.org/library/papers/40316617 | PubMed |
| 38870082 | Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses. | J Antimicrob Chemother | 2024 | https://conductscience.org/library/papers/38870082 | PubMed |
| 38719803 | Population pharmacokinetic modelling of primaquine exposures in lactating women and breastfed infants. | Nat Commun | 2024 | https://conductscience.org/library/papers/38719803 | PubMed |
| 38640243 | Liver-targeted polymeric prodrugs delivered subcutaneously improve tafenoquine therapeutic window for malaria radical cure. | Sci Adv | 2024 | https://conductscience.org/library/papers/38640243 | PubMed |
| 38411047 | Delayed gametocyte clearance in Plasmodium vivax malaria is associated with polymorphisms in the cytochrome P450 reductase (CPR). | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/38411047 | PubMed |
| 37971260 | Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against Plasmodium vivax in Australian Defence Force personnel. | Antimicrob Agents Chemother | 2023 | https://conductscience.org/library/papers/37971260 | PubMed |
| 37652975 | Antimalarial drug discovery: progress and approaches. | Nat Rev Drug Discov | 2023 | https://conductscience.org/library/papers/37652975 | PubMed |
| 37638690 | Pyronaridine: a review of its clinical pharmacology in the treatment of malaria. | J Antimicrob Chemother | 2023 | https://conductscience.org/library/papers/37638690 | PubMed |
| 36928885 | Development of an ectopic huLiver model for Plasmodium liver stage infection. | PLoS One | 2023 | https://conductscience.org/library/papers/36928885 | PubMed |
| 36726785 | Comparative metabolism and tolerability of racemic primaquine and its enantiomers in human volunteers during 7-day administration. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36726785 | PubMed |
| 36321830 | A Novel Ex Vivo Drug Assay for Assessing the Transmission-Blocking Activity of Compounds on Field-Isolated Plasmodium falciparum Gametocytes. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/36321830 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CYP2D6 | 1565 | PubTator's text mining | https://conductscience.org/library/genes/1565 | NCBI Gene |
| PPIG | 9360 | PubTator's text mining | https://conductscience.org/library/genes/9360 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| PRIMAQUINE | CHEMBL506 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL506 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23782898
GET https://conductscience.org/api/papers/v1/23782898/references?page=2